Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

Nader Sanai, Jing Li, Julie Boerner, Karri Stark, Jianmei Wu, Seongho Kim, Alanna Derogatis, Shwetal Mehta, Harshil D. Dhruv, Lance K. Heilbrun, Michael E. Berens, Patricia M. LoRusso

Clin Cancer Res (2018) 24 (16): 3820–3828.

https://doi.org/10.1158/1078-0432.CCR-17-3348

Published: 14 August 2018

View article titled, Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

Includes: Supplementary data

Journal Articles

Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood–Brain Barrier in Glioblastoma Patients Using an IVIVE–PBPK Modeling Approach

Jing Li, Jianmei Wu, Xun Bao, Norissa Honea, Youming Xie, Seongho Kim, Alex Sparreboom, Nader Sanai

Clin Cancer Res (2017) 23 (24): 7454–7466.

https://doi.org/10.1158/1078-0432.CCR-17-0983

Published: 14 December 2017

View article titled, Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood–Brain Barrier in Glioblastoma Patients Using an IVIVE–PBPK Modeling Approach

Includes: Supplementary data

Journal Articles

Complex Disease–, Gene–, and Drug–Drug Interactions: Impacts of Renal Function, CYP2D6 Phenotype, and OCT2 Activity on Veliparib Pharmacokinetics

Jing Li, Seongho Kim, Xianyi Sha, Richard Wiegand, Jianmei Wu, Patricia LoRusso

Clin Cancer Res (2014) 20 (15): 3931–3944.

https://doi.org/10.1158/1078-0432.CCR-14-0791

Published: 31 July 2014

View article titled, Complex Disease–, Gene–, and Drug–Drug Interactions: Impacts of Renal Function, CYP2D6 Phenotype, and OCT2 Activity on Veliparib Pharmacokinetics

Includes: Supplementary data

Journal Articles

Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the γ-Secretase Inhibitor RO4929097

Jianmei Wu, Patricia M. LoRusso, Larry H. Matherly, Jing Li

Clin Cancer Res (2012) 18 (7): 2066–2079.

https://doi.org/10.1158/1078-0432.CCR-11-2684

Published: 01 April 2012

View article titled, Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the γ-Secretase Inhibitor RO4929097

Includes: Supplementary data

NARROW

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood–Brain Barrier in Glioblastoma Patients Using an IVIVE–PBPK Modeling Approach

Complex Disease–, Gene–, and Drug–Drug Interactions: Impacts of Renal Function, CYP2D6 Phenotype, and OCT2 Activity on Veliparib Pharmacokinetics

Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the γ-Secretase Inhibitor RO4929097

Email alerts

AACR Journals

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood–Brain Barrier in Glioblastoma Patients Using an IVIVE–PBPK Modeling Approach

Complex Disease–, Gene–, and Drug–Drug Interactions: Impacts of Renal Function, CYP2D6 Phenotype, and OCT2 Activity on Veliparib Pharmacokinetics

Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the γ-Secretase Inhibitor RO4929097

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only